84 results about "Rasagiline" patented technology

Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.

Disclosed are methods of treating olfactory dysfunction by periodically administering a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to a subject.

The invention relates to rasagiline for treating or preventing nervous system diseases and a transdermal patch of a pharmaceutically acceptable slat of rasagiline. The transdermal patch comprises the rasagiline or the pharmaceutically acceptable slat of rasagiline and at least one hydrophilic polymer substrate. And the pH value of the patch ranges from 3.5 to 6.5. The patch has the characteristics of excellent stability and good control over transdermal release of the rasagiline.

The present invention discloses an oral solid medicinal combination, comprises 0.5 weight percent to 3 weight percent of rasagiline and salt of rasagiline, less than 60 weight percent of pentahydric alcohol and/or hexahydric alcohol and 0.5 weight percent to 3 weight percent of organic acid. The present invention is used for curing the Parkinsonism.

The invention discloses a long-acting sustained-release preparation for resisting Parkinson's disease and a preparation method thereof. The long-acting sustained-release preparation refers to microspheres, each microsphere comprises rasagiline or pharmaceutically acceptable salt thereof and biodegradable high-biocompatibility molecular polymer, and the microspheres includes the microspheres with the average particle size of 0.5-5 micrometers and the microspheres with the average particle size of 20-150 micrometers. The two kinds of microspheres different in particle size are properly matched and used in the pharmaceutical composition, the fluctuation of the concentration of rasagiline in plasma can be significantly reduced, and there is no obvious delayed release period. At the same time, the long-acting sustained-release preparation has no drug releasing phenomenon under the condition of high drug loading.

The invention provides a rasagiline preparation and a preparation method thereof. The rasagiline preparation provided by the invention comprises rasagiline pharmaceutically acceptable salt and pharmaceutically acceptable auxiliary materials comprising a stabilizer and a filling agent. With the method provided by the invention, dissolution rate and stability of the rasagiline preparation are improved, preparation content uniformity is ensured, treatments of crushing and sieving are avoided, and loss and pollution are reduced. The method also has the advantages of simple operation, low cost, and no requirement on special equipment. The method is suitable to be applied on industrial productions.

The invention belongs to the technical field of medicines and relates to an orally disintegrating tablet of Rasagiline or medicine salts thereof and a preparation method thereof. The orally disintegrating tablet comprises the following components in percentage by weight: 0.25-2 percent of Rasagiline or medicine salts thereof, 85-91 percent of spray drying mannitol, 3-10 percent of disintegrant, 0.5-2 percent of flow agent, 0.5-2 percent of lubricant, 0-2 percent of sweetener and 0-2 percent of flavoring agent. The raw materials and the auxiliary materials are uniformly mixed to obtain uniform fine powder which is directly squashed to form tablets. The orally disintegrating tablet of the Rasagiline or the medicine salts thereof has enough hardness, can satisfy the requirements of production, packaging, storage and transportation and also has good taste and shorter disintegration time.